Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition

Cancer Research

Volumn 71, Issue 21, 2011, Pages 6621-6632

  Mamessier, Emilie ^a   Sylvain, Aude ^a   Bertucci, François ^a,c   Castellano, Rémy ^a,b   Finetti, Pascal ^c   Houvenaeghel, Gilles ^c   Charaffe Jaufret, Emmanuelle ^a,c   Birnbaum, Daniel ^a,c   Moretta, Alessandro ^d   Olive, Daniel ^a,c  

^a AIX MARSEILLE UNIVERSITY   (France)

^b INSERM   (France)

^c INSTITUT PAOLI CALMETTES   (France)

^d UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR DNAM; NATURAL KILLER CELL RECEPTOR NKG2D; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL FUNCTION; CONTROLLED STUDY; DISEASE MODEL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOLOGICAL TOLERANCE; IN VIVO STUDY; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MOLECULAR RECOGNITION; MOUSE; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR ESCAPE; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; ESTROGENS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; KILLER CELLS, NATURAL; LIGANDS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; NEOPLASM PROTEINS; NEOPLASMS, HORMONE-DEPENDENT; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; PROGESTERONE; RECEPTORS, IMMUNOLOGIC; RNA, MESSENGER; RNA, NEOPLASM; SELF TOLERANCE; TUMOR ESCAPE;

EID: 80155132470     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-0792     Document Type: Article

References (50)

1. Tirona MT, Sehgal R, Ballester O. Prevention of breast cancer (part I): epidemiology, risk factors, and risk assessment tools. Cancer Invest 2010;28:743-50.
2. Sørlie T, Wang Y, Xiao C, Johnsen H, Naume B, Samaha RR, et al. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics 2006;7:127.
3. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98:10869-74. (Pubitemid 32878711)
4. Bertucci F, Finetti P, Cervera N, Charafe-Jauffret E, Mamessier E, Adelaide J, et al. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res 2006; 66:4636-44.
5. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008;14:518-27. (Pubitemid 351655218)
6. Sabatier R, Finetti P, Cervera N, Lambaudie E, Esterni B, Mamessier E, et al. A gene expression signature identifies two prognostic subgroups of basal breast cancer. Breast Cancer Res Treat 2011;126:407-240.
7. Dewan MZ, Takada M, Terunuma H, Deng X, Ahmed S, Yamamoto N, et al. Natural killer activity of peripheral-blood mononuclear cells in breast cancer patients. Biomed Pharmacother 2009;63:703-6.
8. Dewan MZ, Terunuma H, Takada M, Tanaka Y, Abe H, Sata T, et al. Role of natural killer cells in hormone-independent rapid tumor formation and spontaneous metastasis of breast cancer cells in vivo. Breast Cancer Res Treat 2007;104:267-75. (Pubitemid 47231275)
9. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest 2007;117:1137-46. (Pubitemid 46718398)
10. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol 2008;9:503-10. (Pubitemid 351560519)
11. Moretta L, Bottino C, Pende D, Castriconi R, Mingari MC, Moretta A. Surface NK receptors and their ligands on tumor cells. Semin Immunol 2006;18:151-8. (Pubitemid 43817561)
12. Brandt CS, Baratin M, Yi EC, Kennedy J, Gao Z, Fox B, et al. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med 2009;206:1495-1503.
13. Eisenring M, vom Berg J, Kristiansen G, Saller E, Becher B. IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46. Nat Immunol 2010;11:1030-8.
14. Champsaur M, Lanier LL. Effect of NKG2D ligand expression on host immune responses. Immunol Rev 2010;235:267-85.
15. Moretta A, Sivori S, Vitale M, Pende D, Morelli L, Augugliaro R, et al. Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C molecules in human natural killer cells. J Exp Med 1995;182: 875-84.
16. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Ann Rev Immunol 2001;19:197-223. (Pubitemid 32368034)
17. deMagalhaes-Silverman M, Donnenberg A, Lembersky B, Elder E, Lister J, Rybka W, et al. Posttransplant adoptive immunotherapy with activated natural killer cells in patients with metastatic breast cancer. J Immunother 2000;23:154-60. (Pubitemid 30079836)
18. Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 2011;13:98-107.
19. Charafe-Jauffret E, Ginestier C, Monville F, Finetti P, Adelaide J, Cervera N, et al. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 2006;25:2273-84.
20. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006;7:96.
21. Moesta AK, Norman PJ, Yawata M, Yawata N, Gleimer M, Parham P. Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3. J Immunol 2008;180:3969-79.
22. Blick T, Hugo H, Widodo E, Waltham M, Pinto C, Mani SA, et al. Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44(hi/)CD24 (lo/-) stem cell phenotype in human breast cancer. J Mammary Gland Biol Neoplasia 2010;15: 235-52.
23. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009;69:1302-13.
24. Mamessier E, Sylvain A, Thibult ML, Houvenaeghel G, Jacquemier J, et al. Human and mouse breast cancer cells enhance self-tolerance and promote evasion of NK-cell anti-tumor immunity. J Clin Invest 2011;121:3609-22.
25. Jonkers J, Derksen P. Modeling metastatic breast cancer in mice. J Mammary Gland Biol Neoplasia 2007;12:191-203. (Pubitemid 47215436)
26. Milani V, Stangl S, Issels R, Gehrmann M, Wagner B, Hube K, et al. Antitumor activity of patient-derived NK-cells after cell-based immunotherapy- a case report. J Transl Med 2009;7:50.
27. Markel G, Seidman R, Besser MJ, Zabari N, Ortenberg R, Shapira R, Treves AJ, et al. Natural killer lysis receptor (NKLR)/NKLR-ligand matching as a novel approach for enhancing anti-tumor activity of allogeneic NK-cells. PLoS One 2009;4:e5597.
28. Takaki R, Hayakawa Y, Nelson A, Sivakumar PV, Hughes S, Smyth MJ, et al. IL-21 enhances tumor rejection through a NKG2D-dependent mechanism. J Immunol 2005;175:2167-73. (Pubitemid 41113822)
29. Ruggeri L, Mancusi A, Capanni M, Urbani E, Carotti A, Aloisi T, et al. Donor natural-killer cell allorecognition of missing-self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007;110:433-40. (Pubitemid 47026866)
30. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105:3051-7.
31. Park SW, Bae JH, Kim SD, Son YO, Kim JY, Park HJ, et al. Comparison of level of NKG2D ligands between normal and tumor tissue using multiplex RT-PCR. Cancer Invest 2007;25:299-307.
32. Cao W, Xi X, Hao Z, Li W, Kong Y, Cui L, et al. RAET1E2, a soluble isoformof the UL16-binding protein RAET1E produced by tumor cells, inhibits NKG2D-mediated NK cytotoxicity. J Biol Chem 2007;282: 18922-8. (Pubitemid 47100170)
33. Paschen A, Sucker A, Hill A, Moll I, Zapatka M, Nguyen XD, et al. Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B. Clin Cancer Res 2009;15:5208-15.
34. Madjd Z, Spendlove I, Moss R, Bevin S, Pinder SE, Watson NFS, et al. Upregulation of MICA on high-grade invasive operable breast carcinoma. Cancer Immun 2007:17.
35. Diermayr S, Himmelreich H, Durovic B, Mathys-Schneeberger A, Siegler U, Langenkamp U, et al. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class-I specificities. Blood 2008;111:1428-36. (Pubitemid 351213430)
36. McGilvray RW, Eagle RA, Watson NFS, Al-Attar A, Ball G, Jafferji I, et al. NKG2D ligand expression in human colorectal cancer reveals associations with prognosis and evidence for immunoediting. Clin Cancer Res 2009;15:6993-7002.
37. Jinushi M, Takehara T, Tatsumi T, Kanto T, Groh V, Spies T, et al. Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid. Int J Cancer 2003;104:354-61. (Pubitemid 36249818)
38. Le Maux Chansac B, Missé D, Richon C, Vergnon I, Kubin M, Soria JC, et al. Potentiation of NK-cell-mediated cytotoxicity in human lung adenocarcinoma: role of NKG2D-dependent pathway. Int Immunol 2008;20:801-10. (Pubitemid 351865856)
39. Waldhauer I, Goehlsdorf D, Gieseke F, Weinschenk T, Wittenbrink M, Ludwig A, et al. Tumor-associated MICA is shed by ADAM proteases. Cancer Res 2008;68:6368-76.
40. Cho HM, Rosenblatt JD, Tolba K, Shin SJ, Shin DS, Calfa C, et al. Delivery of NKG2D ligand using an anti-HER2 antibody-NKG2D ligand fusion protein results in an enhanced innate and adaptive antitumor response. Cancer Res 2010;70:10121-30.
41. Iguchi-Manaka A, Kai H, Yamashita Y, Shibata K, Tahara-Hanaoka S, Honda SI, et al. Accelerated tumor growth in mice deficient in DNAM-1 receptor. J Exp Med 2008;205:2959-64.
42. Chan C J, Andrews DM, McLaughlin NM, Yagita H, Gilfillan S, Colonna M, et al. DNAM-1/CD155 interactions promote cytokine and NK-cellmediated suppression of poorly immunogenic melanoma metastases. J Immunol 2010;184:902-11.
43. Castriconi R, Dondero A, Corrias MV, Lanino E, Pende D, Moretta L, et al. Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction. Cancer Res 2004;64:9180-4. (Pubitemid 39665534)
44. Schmudde M, Braun A, Pende D, Sonnemann J, Klier U, Beck JF, et al. Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells. Cancer Lett 2008;272:110-21.
45. Le Maux Chansac B, Moretta A, Vergnon I, Opolon P, Lécluse Y, Grunenwald D, et al. NK-cells infiltrating a MHC class-I-deficient lung adenocarcinoma display impaired cytotoxic activity toward autologous tumor cells associated with altered NK-cell-triggering receptors. J Immunol 2005;175:5790-8. (Pubitemid 41508063)
46. Lakshmikanth T, Burke S, Ali TH, Kimpfler S, Ursini F, Ruggeri L, et al. NCRs and DNAM-1 mediate NK-cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest 2009;119:1251-63.
47. Elboim M, Gazit R, Gur C, Ghadially H, Betser-Cohen G, Mandelboim O. Tumor immunoediting by NKp46. J Immunol 2010;184:5637-44.
48. Clayton A, Mitchell JP, Court J, Mason MD, Tabi Z. Human tumourderived exosomes selectively impair lymphocyte responses to interleukin-2. Cancer Res 2007;67:7458-66. (Pubitemid 47214451)
49. Lee JC, Lee KM, Kim DW, Heo DS. Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol 2004;172:7335-40. (Pubitemid 38747593)
50. Costello RT, Sivori S, Marcenaro E, Lafage-Pochitaloff M, MozziconacciMJ, Reviron D, et al. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood 2002;99:3661-7. (Pubitemid 34534536)